calfactant

This page contains recent news articles, when available, and an overview of calfactant but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

[단�?�]중외제약 �?거액 등 지구촌 vs 비타민 제국 광�?�제약 '전문약'  -  ‎Dec 17, 2009‎
...�?한 광�?�제약�?� 칼팩턴트(Calfactant) 성분�?� 신�?아호�?�곤란�?후군(Respiratory Distress Syndrome �?�하 RDS) 치료제를 출시하기�?� 했다. 신�?아 RDS 질환�?� 조산아 ... 메디컬헤럴드

광�?�제약, '�?�파서프 주' 발매  -  ‎Nov 12, 2009‎
...'칼팩턴트(Calfactant)'성분�?� 신�?아 호�?�곤란�?후군(Respiratory Distress Syndrome �?�하 RDS)치료제가 나왔다. 광�?�제약(대표: 최수부)�?� 최근 미국 오니(Ony)사가 ... 메디포뉴스

Effect of Exogenous Surfactant (Calfactant) in Pediatric Acute Lung...  -  Jan 26, 2005
Douglas F. Willson, MD; Neal J. Thomas, MD; Barry P. Markovitz, MD, MPH; Loren A. Bauman, MD; Joseph V. DiCarlo, MD; Steven Pon, MD; Brian R. Jacobs, MD; ... Journal of American Medical Association - Journal of American Medical Association...

JAMA -- Effect of Exogenous Surfactant (Calfactant) in Pediatric...  -  Jan 26, 2005
You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you ... Journal of American Medical Association - Journal of American Medical Association...

Kissei licenses Pneuma's Calfactant.  -  Jan 28, 2008
Kissei licenses Pneuma's Calfactant. Japan's Kissei Pharmaceutical has entered an agreement with New York, USA-based Pneuma Partners for the R&D and ... $9.94 - Pharma Marketletter - Alacra Store

한�?�약품, 美서 급성호�?�곤란�? 치료제 �?�입  -  Jan 7, 2008
...한�?�약품 (13300�? 200 -1.5%)(대표�?�사 김�?진)�?� 7�?� 미국�?� 뉴마파트너스와 역삼�?� 본사�?서 급성호�?�곤란�?후군(ARDS) 치료물질�?� '칼팩턴트'(Calfactant)�?� 국내 ... 머니투�?��?�

Preterm Infants with Respiratory Distress Syndrome: Incidence Rates...  -  May 7, 2007
For both groups, death rates were nearly 20% lower for babies treated with poractant alfa than for those treated with either beractant or calfactant." ... Free with registration - PR Newswire - AccessMyLibrary.com

Lung Treatments For Premature Babies Under Study  -  May 8, 2007
Previous studies, comparing poractant alfa with calf-derived beractant, have yielded similar results; studies comparing beractant and calfactant, ... sciencedaily.com

… into agreement with Forest Laboratories to co-promote Infasurf...  -  Feb 2, 2005
INO Therapeutics has entered into an agreement with Forest Laboratories Inc to co-promote Infasurf (calfactant) using its sales force, which calls on ... Free with registration - Asia Africa Intelligence Wire - AccessMyLibrary.com

Preterm Infants With RDS -- Surfactant Replacement Therapies Improves...  -  May 12, 2007
For both groups, death rates were nearly 20% lower for babies treated with poractant alfa than for those treated with either beractant or calfactant." ... Medical News Today - Medical News Today (press release)

Lung Treatments For Premature Babies Assessed By Study  -  May 12, 2007
Previous studies, comparing poractant alfa with calf-derived beractant, have yielded similar results; studies comparing beractant and calfactant, ... Medical News Today - Medical News Today (press release)

Study assesses lung treatments for premature babies  -  Sep 5, 2007
Previous studies, comparing poractant alfa with calf-derived beractant, have yielded similar results; studies comparing beractant and calfactant, ... innovations report

Prone Positioning in Children With Acute Lung Injury  -  Nov 9, 2005
Effect of exogenous surfactant (calfactant) in pediatric acute lung injury: a randomized controlled trial. JAMA. 2005;293:470-476. FREE FULL TEXT ... Journal of American Medical Association - Journal of American Medical Association...

Discovery Labs Submits Response to Second FDA Approvable Letter  -  Nov 28, 2007
If approved, Surfaxin would compete against Abbott Laboratories' Survanta (beractant), Forest Pharmaceuticals' Infasurf (calfactant) and Mylan subsidiary ... FDA news - FDA news (subscription)

�?�료계 정론 메디�?�뉴스  -  Jan 5, 2008
...�?�건 박사)는 4�?� 한�?�약품 역삼�?� 본사�?서 급성호�?�곤란�?후군(ARDS) 치료물질 칼팩턴트(Calfactant)�?� 국내 마케팅 �? �?업�? 관한 �?��?�센스 계약�?� 체결했다. ... 메디�?�뉴스

Georgia Code - 16-13-71. (a) A "dangerous drug" means any drug other ...  -  Aug 4, 2005
...(127) Calcium disodium edetate — See exceptions; (128) Calcium gluconogalactogluconate; (129) Calcium levulinate; (129.5) Calfactant; (130) Calusterone; ... Pay-Per-View - Georgia Code - Loislaw

기업규모 불문 개발파�?�프�?��?� 강화 주력  -  Apr 28, 2008
...�?� 외�?�?� 킷세�?�약품�?� 미국 뉴마 파트너스로부터 급성�??�?�? 치료물질�?� '칼팩 턴트'(calfactant)�?� �?국내 개발·�?권�?�, 온콜리스 바�?�오파마는 미국 타쎄레 쎄러퓨 ... 디지틀보사

Press Release: Follow up on Samaritan Pharmaceuticals: License …  -  Jan 23, 2007
They have recently announced the signing of an exclusive license for the marketing and sales of U.S. approved Infasurf (calfactant), a specialist medication ... Pay-Per-View - M2 Presswire - HighBeam Research

Seattle biotech Ikaria merging with New Jersey firm. | Article from...  -  Feb 22, 2007
INO Therapeutics Enters Into Agreement With Forest Laboratories to Co-Promote Infasurf(R) (Calfactant) Intratracheal Suspension. PR Newswire; February 2, ... Pay-Per-View - Seattle Times - HighBeam Research

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on cancernewsnetwork.org lead to other sites. cancernewsnetwork.org does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is CancerNewsNetwork.org responsible for dead or misdirected links.

IF YOU NEED A LINK OR TEXT REMOVED FROM THIS PAGE PLEASE CONTACT cancernewsnetwork (at) live.com.
We will do our best to accommodate your request.